ER-Positive Metastatic Breast Cancer | Oncology Today with Dr Neil Love: Understanding the Current and Future Role of Oral SERDs (Selective Estrogen Receptor Degraders) in the Management of ER-Positive Metastatic Breast Cancer (Companion Faculty Lecture)
MAR 11
Description Community
About

Featuring a slide presentation and related discussion from Dr Komal Jhaveri, including the following topics:

  • Role of ESR1 mutations in sensitivity and resistance to endocrine therapy in patients with ER-positive metastatic breast cancer (0:00)
  • Efficacy and safety of oral SERDs in patients with ER-positive metastatic breast cancer (13:26)
  • Similarities and differences among available and investigational oral SERDs for ER-positive metastatic breast cancer (24:21)

CME information and select publications

Comments